ArticleBritish journal of cancer2019

A phase I study of the HDM2 antagonist SAR405838 combined with the MEK inhibitor pimasertib in patients with advanced solid tumours.

Vincent A de Weger et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.